• RedHill Biopharma sold its 70% interest in Talicia to Apotex for USD 18 million in upfront cash.
• Deal includes up to USD 35 million tied to worldwide net sales milestones.
• Apotex gains full ownership following its earlier purchase of Cumberland’s U.S. branded business, which included the remaining 30% Talicia stake.
• Proceeds are intended to strengthen liquidity and fund a shift toward larger commercial product opportunities in gastrointestinal medicine.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-004329), on August 31, 2026, and is solely responsible for the information contained therein.